AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Daily Turnover | The turnover of Pfizer on 5/29 was $612.30 Million, Ranking 143
ByAinvest
Thursday, May 29, 2025 6:00 pm ET1min read
The turnover of Pfizer on 5/29/2025 was $612.30 million, ranking 143 in today's market, the Volume is 26.21 million.
Pfizer(PFE) shares closed at $23.45, up 1.16% on 5/29/2025, up 1.78% in the last 5 trading days, down 3.93% this month, down 11.61% year-to-date and down 16.84% in the last 52 weeks.
*If the company has been listed for less than 52 weeks, the 52-week gain is the gain since the listing.
(The same applies for less than 1 month, or less than 5 trading days)
【History Turnover】
| Date | Turnover | Volume | Price | Performance |
|---|---|---|---|---|
| 5/29/2025 | $612.30 million | 26.21 million | $23.45 | 1.16% |
| 5/28/2025 | $855.33 million | 36.74 million | $23.18 | -1.82% |
| 5/27/2025 | $851.88 million | 36.16 million | $23.61 | 1.24% |
| 5/23/2025 | $822.81 million | 35.41 million | $23.32 | 1.22% |
| 5/22/2025 | $887.24 million | 38.60 million | $23.04 | 0.00% |
【Company Profile】
Pfizer Inc. was incorporated under the laws of the State of Delaware on June 2, 1942. The company is a research-based, global biopharmaceutical company. The Company applies science and global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture and distribution of healthcare products, including innovative medicines and vaccines. The company works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of the time. The company collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet